Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT
CAMBRIDGE, Mass., May 10, 2023 — Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel. In this new role, Ms.
Collaboration to combine Korro’s RNA editing technology and Genevant’s LNP technology CAMBRIDGE, Mass., VANCOUVER, British Columbia, and BASEL, Switzerland, March 7, 2023 – Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Genevant
CAMBRIDGE, Mass., February 28, 2023 — Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Steve Colletti, Ph.D. as Chief Scientific Officer. Dr. Colletti is a highly respected scientist and seasoned
CAMBRIDGE, Mass., January 4, 2023 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41 st Annual J.P.
Venkat Krishnamurthy appointed Senior Vice President, Head of Platform Stephanie Engels appointed Senior Vice President, Head of People and Culture CAMBRIDGE, Mass., November 8, 2022— Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic
CAMBRIDGE, Mass., June 6, 2022 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference, being held in New
Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors Funding will advance Korro’s proprietary editing platform that co-opts endogenous human RNA editing system Advancing a novel class of RNA editing drug candidates for rare and
CAMBRIDGE, Mass., January 5, 2022 — Korro Bio, Inc. , a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 40 th Annual J.P.
CAMBRIDGE, Mass., November 22, 2021 — Korro Bio, Inc. , an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences, as
